Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804318 · ClinicalTrials.gov registry record · NA
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
A NA study of Prostate Cancer, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 7
- Study locations
NCT05804318 is a NA study of Prostate Cancer that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 132 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05804318, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 7
- Study locations
Study Summary
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Conditions Studied
Interventions
- DEVICE Daily adaptive SBRT with urethral sparing
Study Locations (7)
California
- Duarte Cancer Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
Massachusetts
- Brigham and Women's Hospital - Boston
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Saarland
- Universitätsklinikum des Saarlandes (Saarland Univerisity Hospital) - Homburg
Navarre
- Hospital Universitario de Navarra - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2031-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05804318
The ClinicalTrials.gov registry entry for NCT05804318 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Varian, a Siemens Healthineers Company, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Daily adaptive SBRT with urethral sparing is the first listed.
NCT05804318 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT05804318 about?
NCT05804318 is a clinical study titled "Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer". This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the p...
What is the current status of trial NCT05804318?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2023-04-13. Estimated completion is 2031-07.
What conditions does trial NCT05804318 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05804318?
The interventions under investigation include: Daily adaptive SBRT with urethral sparing (DEVICE).
Who is sponsoring clinical trial NCT05804318?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804318 being conducted?
This trial has 7 study locations across California, Massachusetts, Missouri, Pennsylvania, Saarland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.